Do Analysts Expect Seelos Therapeutics Inc (SEEL) Stock to Rise After It Is Down -27.27% in a Month?

Analysts who follow Seelos Therapeutics Inc (SEEL) on average expect it to rise 691.67% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy. That average rating earns Seelos Therapeutics Inc an Analyst Ranking of 74, which means it ranks higher than 74 of stocks, based on data compiled by InvestorsObserver.

Wall Street analysts are rating SEEL a Strong Buy today. Find out what this means to you and get the rest of the rankings on SEEL!

See Full SEEL Report

Why are Analyst Ratings Important?

Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions **before** a quarterly report that could be worse than expected. InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.

What's Happening With Seelos Therapeutics Inc Stock Today?

Seelos Therapeutics Inc (SEEL) stock is trading at $1.20 as of 2:05 PM on Friday, Jan 21, a drop of -$0.05, or -3.84% from the previous closing price of $1.25. The stock has traded between $1.18 and $1.24 so far today. Volume today is 1,986,623 compared to average volume of 2,131,628. Click Here to get the full Stock Report for Seelos Therapeutics Inc stock.